Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by woundedkneeon Jun 08, 2021 6:49am
335 Views
Post# 33346205

My investment

My investmentSo where does my 140K plus investment go from here? It is obvious in a downtrend. A trend that seems to be headed further south than most here had anticipated. So with all the lofty price targets out there, can they now be a guide for investing in ATE? That certainly had a great influence on me, along with my previous information about their pipelines. So what or whom is to blame for the lackluster performance of this stock? A stock, supposedly about to enter phase 3 trials and a promise that a Nasdaq listing is scheduled for later this year. Seems to me there may be a lack of transparency here that leads to mistrust. Those are hard statements considering the hard work of both parties to come to an amalgamation agreement. That in itsself was a huge win for shareholders in my opinion and that alone should have moved the stock up instead of down. The dilution caused by this should have been negated by the gain of 15% in royalties as outlined in the amalgamation agreement. So what is the answer? Maybe it's something as simple as this sector being out of favor. I don't know the answer, but at least we don't have Dan selling shares. If this goes to two bucks, I'll still be here hoping for a five or 6 bagger. Looks like the next 6 months will tell us all where we are headed. And then again, there always is the unexpected that could happen tomorrow. gl
<< Previous
Bullboard Posts
Next >>